Innate Pharma (IPHA) EBT (2019 - 2025)

Innate Pharma (IPHA) has reported EBT for 7 consecutive years, with -$56.0 million the latest figure, recorded in Q4 2025.

• Quarterly EBT rose 0.59% year-over-year to -$56.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$164.7 million (down 72.05% YoY) and the FY2025 annual result came in at -$56.0 million, up 0.59% from the prior year.
• EBT slipped to -$56.0 million in Q4 2025 per IPHA's latest filing, from -$24.3 million in the prior quarter.
• Over the last five years, EBT for IPHA reached as high as -$2.7 million in Q2 2023 and fell as low as -$56.3 million in Q4 2024.
• A 5-year average of -$30.7 million and a median of -$27.0 million in 2021 frame the typical range for EBT.
• Annual changes were most pronounced in 2021 — EBT plunged 5669.0% — and 2022, when it surged 65.66%.
• Year by year, EBT stood at -$54.4 million in 2021, then jumped by 65.66% to -$18.7 million in 2022, then surged by 53.91% to -$8.6 million in 2023, then slumped by 553.51% to -$56.3 million in 2024, then climbed by 0.59% to -$56.0 million in 2025.
• According to Business Quant data, EBT over the past three periods registered -$56.0 million, -$24.3 million, and -$56.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.